Table 1. Characteristics of participants in the included studies.
| studies | location | Number of centers | Number of patients | Age (years) | Characteristics and stages of condition |
|---|---|---|---|---|---|
| Jiang MY 2013 [41] |
China: Shanghai |
1 | 30/30 | 46~75 | Advanced lung cancer Lung cancer |
| Zhang LL 2016 [42] |
China: Taizhou |
1 | 38/36 | 62.8 | undergoing 2–4 21-day cycles of cisplatin-based chemotherapy (ECOG PS) 0–3 |
| Larkey LK 2015 [43] |
US: Arizona |
1 | 42/45 | 40~75 | Stages 0-III breast cancer; 6 months to 5 years past primary treatment |
| Burschka JM 2014 [44] |
Germany: Bayreuth |
115/17 | 15/17 | 42.6/43.6 | Any multiple sclerosis type, ability to walk without a walking aid, EDSS score <5, and relapse-free for the past 4 weeks |
| Castro-Sánchez AM 2012 [45] |
Spain: Granada |
1 | 36/35 | 18~75 | Multiple sclerosis, VAS pain score >4 for at least 2 months, EDSS≤7.5 |
| Wang CC 2008 [46] |
US: Boston |
1 | 10/10 | ≥18 | Functional class I and II rheumatoid arthritis |
| Irwin MR 2014 [47] |
US: Los Angeles |
1 | 48/25 | > 55 | Chronic and primary insomnia |
| Chan AW 2013 [48] |
China: Hong Kong |
5 | 70/67 | 55~88 | COPD and were ambulatory |
| Lin Li 2012 [49] |
China: Hengyang |
1 | 31/33 | > 60 | Fatigue without serious ailments |
| Li GP 2011 [50] |
China: Hunan |
1 | 38/36 | > 50 | Fatigue without serious ailments |
Note: Studies are listed by lead author and publication year. Age is stated as mean and/or range. Number of patients is shown as the number of patients in the intervention and control groups.